Waltham, Mass. — Revvity, Inc. reported higher second-quarter revenue and adjusted earnings and raised its full-year 2026 financial guidance as demand improved across its customer base.
Revenue for the quarter ended July 5 increased to $730 million from $720 million in the same period last year. GAAP earnings from continuing operations were 48 cents per share, compared with 47 cents per share a year earlier.
Adjusted earnings from continuing operations rose to $1.41 per share from $1.18 per share.
GAAP operating income from continuing operations was $89 million, compared with $91 million in the prior-year period. The latest quarter included $16 million in tariff-related refunds.
The GAAP operating margin declined to 12.2 percent from 12.6 percent.
Adjusted operating income increased to $211 million from $192 million, while the adjusted operating margin expanded to 28.9 percent from 26.6 percent.
“Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base,” said Prahlad Singh, President and Chief Executive Officer of Revvity.
“As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth,” Singh said.
Revvity also announced a definitive agreement to divest its immunodiagnostics business in China, which accounted for about 6 percent of the company’s total revenue in fiscal 2025.
The transaction is expected to close by the end of 2027, subject to regulatory approvals and other customary closing conditions.
The company presented its second-quarter results on both a reported and pro forma basis. Its forward-looking guidance excludes the China immunodiagnostics business.
Pro forma revenue increased 4 percent to $711 million from $681 million, while pro forma organic revenue grew 3 percent.
Pro forma earnings from continuing operations were 52 cents per share, compared with 48 cents per share a year earlier.
Pro forma adjusted earnings increased to $1.41 per share from $1.15 per share. The latest result included about 11 cents per share from tariff-related refunds.
Pro forma adjusted operating income rose to $209 million from $180 million. The pro forma adjusted operating margin increased to 29.3 percent from 26.5 percent.
Revenue in Revvity’s Life Sciences segment declined to $359 million from $366 million. Pro forma revenue decreased 2 percent, while pro forma organic revenue fell 3 percent.
Life Sciences adjusted operating income decreased to $112 million from $115 million, and the segment’s adjusted operating margin declined to 31.1 percent from 31.6 percent.
Diagnostics revenue increased to $371 million from $354 million. Pro forma revenue rose 12 percent, while pro forma organic revenue increased 11 percent.
Diagnostics adjusted operating income climbed to $113 million from $89 million. The segment’s adjusted operating margin expanded to 30.4 percent from 25.2 percent.
For the full year, Revvity now expects pro forma revenue of $2.83 billion to $2.86 billion.
The company forecasts pro forma organic revenue growth of 4 percent to 5 percent and pro forma adjusted earnings of $5.30 to $5.40 per share.
